UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of October 2023
Commission File Number: 001-38104
IMMURON LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South,
Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes ☐ No
☒
If “Yes” is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82-
IMMURON LIMITED
EXPLANATORY NOTE
Immuron Limited (the “Company”) published
one announcement (the “Public Notices”) to the Australian Securities Exchange on October 18, 2023 titled:
|
- |
“Travelan Clinical Study Cohort 2 commences” |
A copy of the Public Notice is attached as an exhibit to this report
on Form 6-K.
This report on Form 6-K (including the exhibit
hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.
EXHIBITS
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
IMMURON LIMITED |
|
|
|
|
|
|
|
|
Date: October 18, 2023 |
By: |
/s/ Phillip Hains |
|
|
Phillip Hains |
|
|
Company Secretary |
3
Exhibit 99.1
Travelan® Clinical Study Cohort
2 commences
Highlights:
| ● | Second
cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial |
| | |
| ● | Clinical
Trial to examine a dosing regimen for Travelan® more suited to the US military
has commenced the second cohort |
| | |
| ● | The clinical study 6 month follow up of Cohorts
1 and 2 anticipated to be completed in April 2024 |
| | |
| ● | Travelan® is known to protect against
the onset of Traveler’s diarrhea (TD), the most common illness reported by travelers |
Melbourne, Australia, October 18, 2023: Immuron
Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce the second
cohort of 34 participants have commenced the clinical trial to evaluate the efficacy of Travelan® to prevent infectious diarrhea caused
by enterotoxigenic Escherichia coli (ETEC).
The clinical study is being led by Principal
Investigator Dr Mohamed Al-Ibrahim at the Pharmaron CPC FDA inspected Clinical Research Facility Inpatient Unit located in Baltimore,
Maryland US. The Phase 2 clinical trial is designed to evaluate the safety and protective efficacy of Travelan® compared
to a placebo in a controlled human infection model (CHIM). The primary efficacy outcome is prevention and/or reduction of moderate to
severe diarrhea. ClinicalTrials.gov Identifier: NCT05933525.
The first cohort in-patient stage of the study
was completed in August 2023. Immuron received confirmation that a second cohort of 34 study participants were admitted to the Pharmaron
inpatient facility and randomized to receive either Travelan® or placebo. The inpatient phase for the second cohort will
be completed by the end of October 2023. All study participants will return as outpatients for 2 weeks, 1 month and 6 month follow-up
visits. Headline results from the clinical trial are anticipated to be reported in June 2024.
Infectious diarrhea is the most common illness
reported by travelers visiting developing countries and among US troops deployed overseas. The morbidity and associated discomfort stemming
from diarrhea decreases daily performance, affects judgment, decreases morale and declines operational readiness. The first line of treatment
for infectious diarrhea is the prescription of antibiotics. Unfortunately, in the last decade, several enteric pathogens have demonstrated
increasing resistance to commonly prescribed antibiotics. In addition, traveler’s diarrhea is now recognized by the medical community
to result in post-infectious sequelae, including post-infectious irritable bowel syndrome (IBS) and several post-infectious autoimmune
diseases. A preventative treatment that defends against infectious enteric diseases is a high priority objective for the US Military.
This release has been authorised by the directors
of Immuron Limited.
- - - END - - -
COMPANY CONTACT:
Steven Lydeamore
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com
About Travelan®
Travelan®
is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea,
a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce.
Travelan® is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when
taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with traveler’s diarrhea.
In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated
to reduce the risk of Traveler’s Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada,
Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Traveler’s
Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection.
About Traveler’s diarrhea
Traveler’s diarrhea
is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating,
and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant
causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella
spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused
with traveler’s diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable.
About Immuron
Immuron Limited (ASX:
IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal
antibodies for the treatment of inflammatory mediated and infectious diseases.
For more information
visit: http://www.immuron.com
FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development
programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations
and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock
value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth
strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the
results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties
relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and
intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in
our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Immuron (NASDAQ:IMRN)
過去 株価チャート
から 4 2024 まで 5 2024
Immuron (NASDAQ:IMRN)
過去 株価チャート
から 5 2023 まで 5 2024